($GSK) GlaxoSmithKline Announces Swine Flu Vaccine Orders Increase

October 8th, 2009

Yesterday, GlaxoSmithKline (GSK) announced that orders for its pandemic (H1N1) adjuvanted vaccine have increased significantly in the past two months. On Aug 4, the company reported that it had contracts for the supply of 291 million doses of the swine flu vaccine. The company had several agreements in place with the U.S. Government for the supply of pandemic products worth $250 million.

The company has reported that it received 22 government orders for the supply of an additional 149 million doses of the vaccine, bringing the total order to 440 million doses. The company is in discussions with several governments for further supplies.

GlaxoSmithKline started shipping the first supplies of the vaccine earlier this week. The vaccines will be delivered in the fourth quarter of 2009 and the first half of 2010. Vaccine deliveries are contingent on several factors such as government import/export regulations, regulatory approvals, approvals for outsourced packaging and filling as well as testing required by reference laboratories.

While GlaxoSmithKline’s vaccine received approval in the European Union in late Sep 2009, the U.S. approval is yet to come.

The current outbreak of swine flu pandemic can prove to be a major opportunity for vaccine manufacturers. In addition to GlaxoSmithKline, other major players in the vaccine segment such as Sanofi-Aventis (SNY), Novartis (NVS), Baxter International (BAX) and AstraZeneca (AZN) are looking to market their vaccines at the earliest.

In fact, several companies including Sanofi Pasteur, the vaccine division of Sanofi-Aventis, Novartis Vaccines and Diagnostics Limited, the vaccine and diagnostics arm of Novartis, MedImmune LLC, a subsidiary of AstraZeneca and CSL Limited of Australia, have already received approval from the U.S. Food and Drug Administration for their swine flu vaccines.

Zacks Investment Research
View original at: Zacks.com News Feed

More on this topic (What's this?)
FDA Approves Glaxo’s (NYSE: GSK) Cervical Cancer Vaccine (, 10/16/09)
A few Quick Words (Fusion Investing and Analysis, 10/25/09)
H1N1: Governments Increase Orders for Glaxo's Vaccine (Shocked Investor, 10/6/09)
Biota Holding’s Relenza Royalties Tops Estimates (Fusion Investing and Analysis, 10/28/09)
Read more on GlaxoSmithKline, Influenza outbreak at Wikinvest

Related Posts:

  1. (BAX) Baxter International Fails to Deliver Swine Flu VaccineBaxter International Inc. (BAX) has failed to deliver on its pledge to the U.K. government...
  2. (SNY) FDA Approves First H1N1 VaccineIn a major achievement towards vaccinating people against the H1N1 virus, yesterday the US Food...
  3. (SNY) Sanofi Grows Strong on VaccinesWe are pleased to hear that India’s Shantha Biotechnics received a $340 million contract to...
  4. (NVAX) Novavax Scores Major BreakthroughWe are pleased to hear that the vaccine developer Novavax (NVAX) has made a major...
  5. (AZN) Almost 25 Pharmaceutical Companies are Racing to Bring H1N1the Vaccine to MarketAlthough we are waiting eagerly for the first H1N1 vaccine to hit the market, it...
  6. (GSK) Glaxo’s Vaccine Portfolio ExpandedYesterday, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline’s (GSK) Hiberix, a Haemophilus influenzae...


Search Posts by Tag: | | | | | | | | | | Drug Manufacturers - Major | Healthcare

RSS Feeds by Tag: AstraZeneca plc | AZN | BAX | Baxter International Inc | Glaxosmithkline plc | GSK | Novartis AG | NVS | Sanofi-Aventis | SNY | Drug Manufacturers - Major | Healthcare |

Other Posts by: | RSS Feed for this author